Video Programs

In this closing segment, Dr. Peter Voorhees, Dr. Luciano Costa, and Dr. Doris Hansen discuss the limitations of available evidence for sequencing therapies in relapsed/refractory multiple myeloma.

In this segment, Dr. Peter Voorhees presents a modified case involving a patient in their early 70s with relapsed multiple myeloma whose disease has become refractory to both lenalidomide and daratumumab following frontline daratumumab, lenalidomide, and dexamethasone therapy.

In this segment, Dr. Peter Voorhees opens the panel discussion on sequencing and patient selection across the multiple myeloma treatment continuum.

In this segment, Dr. Peter Voorhees and Dr. Doris Hansen discuss the safety profile and post-treatment management of CAR T-cell therapy in relapsed/refractory multiple myeloma, with emphasis on considerations for community oncologists caring for patients after discharge from the CAR T-cell center.

In this segment, Dr. Peter Voorhees and Dr. Doris Hansen discuss how the findings from CARTITUDE-2 Cohort A relate to the randomized CARTITUDE-4 study and how these data inform consideration of CAR T-cell therapy in relapsed/refractory multiple myeloma.

In this segment, Dr. Peter Voorhees introduces the role of BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma and its movement into earlier lines of treatment.

In this segment, Dr. Peter Voorhees discusses treatment selection with bispecific antibodies in relapsed/refractory multiple myeloma, focusing on patients with prior CD38 antibody exposure.

In this segment, Dr. Peter Voorhees discusses the MonumenTAL-3 study evaluating the GPRC5D-directed bispecific antibody talquetamab in earlier-line relapsed/refractory multiple myeloma.

In this segment, Dr. Peter Voorhees introduces the evolving role of bispecific antibodies in relapsed/refractory multiple myeloma, highlighting the movement of these therapies into earlier lines of treatment.

In this segment, Dr. Luciano Costa provides practical considerations for managing patients with newly diagnosed multiple myeloma receiving frontline quadruplet therapy.

In this segment, Dr. Peter Voorhees and Dr. Luciano Costa discuss how treatment selection can be individualized for patients with newly diagnosed multiple myeloma, including considerations when choosing between triplet and quadruplet regimens.

In this segment, Dr. Peter Voorhees and Dr. Luciano Costa discuss the design and clinical implications of the CEPHEUS trial in newly diagnosed multiple myeloma, with particular attention to patients who were transplant-ineligible or transplant-deferred.

In this segment, Dr. Peter Voorhees introduces the Targeted™ Oncology Investigator Perspectives program and outlines the evolving treatment landscape in newly diagnosed multiple myeloma, including the movement of novel therapies into earlier lines of treatment.

Martin Dietrich, MD, PhD, tells community oncologists to build in access to second opinions, often by telemedicine, and says he would rather be slow and right than fast and wrong, because a less effective first choice drives resistance that later agents cannot fully recover.

Ticiana Leal, MD, argues that trials need more patient-reported outcomes and quality of life measures, since patients with ROS1-positive advanced non-small cell lung cancer now stay on oral therapy for years and the effect on daily life is poorly captured.

Martin Dietrich, MD, PhD, says he manages neurologic adverse events reactively rather than proactively, because he cannot predict who will develop them and because on-target effects tend to appear early.

Martin Dietrich, MD, PhD, separates an agent working in the brain from an agent acting on the brain, and explains that structural overlap in the adenosine triphosphate (ATP) binding pocket makes TRK family inhibition difficult to avoid.

Martin Dietrich, MD, PhD, says duration of response and progression-free survival converge in the untreated setting, because response rates approach the whole population, so the two numbers carry much the same information.

Wade Iams, MD, frames central nervous system management around radiation sparing.

Martin Dietrich, MD, PhD, says the first move at progression is to extend frontline therapy rather than abandon it, looking for oligometastatic patterns that stereotactic radiation can handle while the inhibitor continues; a patient progressing at four years with two or three new lesions is a candidate.

Wade Iams, MD, says progression-free survival (PFS) drives his frontline choice, since median overall survival remains years away in ROS1-positive advanced non-small cell lung cancer and no head-to-head comparison exists.

Wade Iams, MD, says the guidance has changed on what to do when a ROS1 result lands after chemoimmunotherapy has already started.

Wade Iams, MD, says adding RNA-based next-generation sequencing (NGS) to DNA-based NGS identifies about 15% more patients with actionable fusions, and urges clinicians to confirm whether the panel they ordered includes RNA at all, since the report rarely makes that obvious.

Dr. Monty Pal concludes the program by discussing how the treatment landscape for advanced renal cell carcinoma (RCC) may evolve as new clinical evidence emerges.

Dr. Monty Pal concludes his discussion on treatment sequencing in advanced renal cell carcinoma (RCC) by summarizing how he applies current guideline recommendations alongside individualized clinical decision making in routine practice.

Dr. Monty Pal reviews emerging clinical evidence evaluating belzutifan-based treatment strategies in advanced renal cell carcinoma (RCC), with particular focus on the LITESPARK-011 trial comparing lenvatinib plus belzutifan with cabozantinib.

Dr. Monty Pal discusses the growing importance of quality of life and long-term tolerability when selecting subsequent therapies for advanced renal cell carcinoma (RCC).

Dr. Monty Pal discusses how patient- and disease-specific characteristics influence treatment sequencing decisions for advanced renal cell carcinoma (RCC) beyond the first-line setting.

Dr. Monty Pal discusses his approach to selecting second-line therapy for advanced renal cell carcinoma (RCC) based on the type of first-line immunotherapy regimen previously received.

Dr. Monty Pal begins the discussion on treatment sequencing in advanced renal cell carcinoma (RCC) by emphasizing the importance of optimizing first-line therapy, noting that many patients may not receive multiple subsequent lines of treatment.